Candel Therapeutics (NASDAQ:CADL – Get Free Report) had its price target upped by stock analysts at Canaccord Genuity Group from $20.00 to $25.00 in a report issued on Wednesday,Benzinga reports. The ...

Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a ...

Data from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Candel Therapeutics (CADL – Research Report) and ...

Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. Find out why I rate CADL stock ...

Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop ...

Candel Therapeutics (CADL) announced final overall survival data from the completed randomized controlled phase 2 clinical trial of CAN-2409 ...

There is a rich history of Long Island boys basketball, from the 1950s with superstars such as Jim Brown of Manhasset and ...

Candel Therapeutics (Nasdaq: CADL) has released final data from a Phase II trial of its investigational immunotherapy, ...

Candel Therapeutics reports improved survival rates with CAN-2409 in pancreatic cancer, showcasing potential efficacy and a favorable safety profile. Positive final survival data showed a notable ...

(RTTNews) - Candel Therapeutics (CADL) announced positive final survival data from its completed randomized Phase 2 clinical trial of CAN-2409 in patients with borderline resectable pancreatic ...